Cargando…

Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer

PURPOSE: Ovarian cancer (OC) has the highest mortality among gynecological malignancies. Therefore, it is urgent to explore prognostic biomarkers to improve the survival of OC patients. One of the most prominent metabolic characteristics of cancer is effective glycolysis. Hexokinase 1 (HK1), as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanqing, Tian, Huining, Luo, Haoge, Fu, Jiaying, Jiao, Yan, Li, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667154/
https://www.ncbi.nlm.nih.gov/pubmed/33204111
http://dx.doi.org/10.2147/OTT.S270688
_version_ 1783610248020361216
author Li, Yanqing
Tian, Huining
Luo, Haoge
Fu, Jiaying
Jiao, Yan
Li, Yang
author_facet Li, Yanqing
Tian, Huining
Luo, Haoge
Fu, Jiaying
Jiao, Yan
Li, Yang
author_sort Li, Yanqing
collection PubMed
description PURPOSE: Ovarian cancer (OC) has the highest mortality among gynecological malignancies. Therefore, it is urgent to explore prognostic biomarkers to improve the survival of OC patients. One of the most prominent metabolic characteristics of cancer is effective glycolysis. Hexokinase 1 (HK1), as the first rate-limiting enzyme in glycolysis, is closely related to cancer progression. However, the role of HK1 in OC remains unclear. MATERIALS AND METHODS: The Cancer Genome Atlas (TCGA) database was used to detect the expression of HK1 in OC patients. The chi-squared test was performed to examine the correlations between HK1 and patients’ clinical characteristics. Survival analyses were undertaken to determine the relationship between HK1 and patient survival, while the univariate/multivariate Cox model was used to evaluate the role of HK1 in patient prognosis. Gene Set Enrichment Analysis (GSEA) was performed to ascertain the related signaling pathways of HK1. RT-qPCR was implemented to validate the mRNA expression of HK1 in OC cells. MTT was used to detect cell viability after adding 2DG and knocking down HK1 in OC cells. HK1 protein expression was examined by Western blotting. Glucose uptake, lactate production, and ATP assays were undertaken following knockdown of HK1 in OC cells. Colony formation assays were performed to determine OC cell proliferation after HK1 knockdown. Transwell and wound healing assays were carried out to detect the invasion and migration of OC cells after HK1 knockdown. RESULTS: We found that HK1 expression was increased in OC tissues and cells, and HK1 was related to the clinical characteristics of OC patients. Survival analysis revealed that OC patients in the HK1 overexpression group had poor survival. Moreover, univariant/multivariate analyses showed that HK1 may be an independent biomarker for the poor prognosis of OC patients. OC cell viability and proliferation decreased after knockdown of HK1. Consistently, glucose uptake, lactic acid production, ATP production, invasion, and migration were also decreased. Finally, GSEA enrichment analysis and Western blotting showed that HK1 was involved in MAPK/ERK signaling. CONCLUSION: HK1 may be a biomarker for the poor prognosis of OC patients and a potential therapeutic target.
format Online
Article
Text
id pubmed-7667154
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76671542020-11-16 Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer Li, Yanqing Tian, Huining Luo, Haoge Fu, Jiaying Jiao, Yan Li, Yang Onco Targets Ther Original Research PURPOSE: Ovarian cancer (OC) has the highest mortality among gynecological malignancies. Therefore, it is urgent to explore prognostic biomarkers to improve the survival of OC patients. One of the most prominent metabolic characteristics of cancer is effective glycolysis. Hexokinase 1 (HK1), as the first rate-limiting enzyme in glycolysis, is closely related to cancer progression. However, the role of HK1 in OC remains unclear. MATERIALS AND METHODS: The Cancer Genome Atlas (TCGA) database was used to detect the expression of HK1 in OC patients. The chi-squared test was performed to examine the correlations between HK1 and patients’ clinical characteristics. Survival analyses were undertaken to determine the relationship between HK1 and patient survival, while the univariate/multivariate Cox model was used to evaluate the role of HK1 in patient prognosis. Gene Set Enrichment Analysis (GSEA) was performed to ascertain the related signaling pathways of HK1. RT-qPCR was implemented to validate the mRNA expression of HK1 in OC cells. MTT was used to detect cell viability after adding 2DG and knocking down HK1 in OC cells. HK1 protein expression was examined by Western blotting. Glucose uptake, lactate production, and ATP assays were undertaken following knockdown of HK1 in OC cells. Colony formation assays were performed to determine OC cell proliferation after HK1 knockdown. Transwell and wound healing assays were carried out to detect the invasion and migration of OC cells after HK1 knockdown. RESULTS: We found that HK1 expression was increased in OC tissues and cells, and HK1 was related to the clinical characteristics of OC patients. Survival analysis revealed that OC patients in the HK1 overexpression group had poor survival. Moreover, univariant/multivariate analyses showed that HK1 may be an independent biomarker for the poor prognosis of OC patients. OC cell viability and proliferation decreased after knockdown of HK1. Consistently, glucose uptake, lactic acid production, ATP production, invasion, and migration were also decreased. Finally, GSEA enrichment analysis and Western blotting showed that HK1 was involved in MAPK/ERK signaling. CONCLUSION: HK1 may be a biomarker for the poor prognosis of OC patients and a potential therapeutic target. Dove 2020-11-11 /pmc/articles/PMC7667154/ /pubmed/33204111 http://dx.doi.org/10.2147/OTT.S270688 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Yanqing
Tian, Huining
Luo, Haoge
Fu, Jiaying
Jiao, Yan
Li, Yang
Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title_full Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title_fullStr Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title_full_unstemmed Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title_short Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer
title_sort prognostic significance and related mechanisms of hexokinase 1 in ovarian cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667154/
https://www.ncbi.nlm.nih.gov/pubmed/33204111
http://dx.doi.org/10.2147/OTT.S270688
work_keys_str_mv AT liyanqing prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer
AT tianhuining prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer
AT luohaoge prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer
AT fujiaying prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer
AT jiaoyan prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer
AT liyang prognosticsignificanceandrelatedmechanismsofhexokinase1inovariancancer